MRIMath LLC, a company in Alabama, has received FDA clearance for its cyber device and AI system designed to streamline glioblastoma care. The i2Contour device provides AI-powered tools to help physicians save time when evaluating brain imaging, allowing for quicker patient care. The system offers quicker labeling, volume measurement, and precision monitoring capabilities for glioblastoma treatment. The technology aims to improve outcomes for patients with glioblastoma by providing advanced tools for rapid computation of segmented imaging changes. The AI models produce precise volume measurements comparable to those made by radiologists, showing promising results in improving efficiency and accuracy of glioblastoma diagnosis and treatment.
Source link
FDA clears cyber device, AI system to address glioblastoma
